Arcus Biosciences, Inc.
RCUS
$9.16
$0.030.33%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -40.51% | 120.51% | 119.17% | 104.13% | 99.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -40.51% | 120.51% | 119.17% | 104.13% | 99.16% |
| Cost of Revenue | 21.50% | 29.43% | 32.94% | 19.03% | -4.87% |
| Gross Profit | -283.93% | 42.57% | 45.45% | 62.70% | 70.37% |
| SG&A Expenses | -2.52% | 2.56% | 4.31% | 8.04% | 8.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.48% | 24.29% | 26.64% | 19.82% | 16.51% |
| Operating Income | -74.40% | 8.82% | 7.74% | 12.78% | 16.39% |
| Income Before Tax | -71.81% | 6.31% | 6.60% | 13.38% | 18.05% |
| Income Tax Expenses | -75.00% | -83.33% | -80.00% | 0.00% | 100.00% |
| Earnings from Continuing Operations | -69.26% | 7.82% | 7.85% | 13.24% | 17.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.26% | 7.82% | 7.85% | 13.24% | 17.20% |
| EBIT | -74.40% | 8.82% | 7.74% | 12.78% | 16.39% |
| EBITDA | -76.76% | 9.64% | 9.15% | 13.73% | 17.47% |
| EPS Basic | -35.07% | 25.36% | 21.06% | 21.42% | 19.46% |
| Normalized Basic EPS | -48.38% | 29.85% | 25.94% | 27.56% | 26.35% |
| EPS Diluted | -35.07% | 25.36% | 21.09% | 21.45% | 19.49% |
| Normalized Diluted EPS | -48.38% | 29.85% | 25.94% | 27.56% | 26.35% |
| Average Basic Shares Outstanding | 20.58% | 21.84% | 17.14% | 12.34% | 6.70% |
| Average Diluted Shares Outstanding | 20.58% | 21.84% | 17.14% | 12.34% | 6.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |